肺癌基因突变的概率和对应的靶向治疗

Gene	Alteration	Frequency in  NSCLC
AKT1	Mutation	1%
ALK	Rearrangement	3–7%
BRAF	Mutation	1–3%
DDR2	Mutation	~4%
EGFR	Mutation	10–35%
FGFR1	Amplification	20%
HER2	Mutation	2–4%
KRAS	Mutation	15–25%
MEK1	Mutation	1%
METa	Amplification	2–4%
NRAS	Mutation	1%
PIK3CA	Mutation	1–3%
PTEN	Mutation	4–8%
RET	Rearrangement	1%
ROS1​a	Rearrangement	1%

表格颜色传不上，用图片传一次。

Drugsapproved in NSCLC.
Drugs approved in NSCLC but for other molecular subtype.
Drugs approved in other cancer.
Drugs in clinical development.

谢谢

感谢分享，！想问下出处，好更仔细地看看。

感谢楼主分享！